IP Group (IPO) H2 2025 earnings summary

Executive summary

• Achieved 13% year-over-year growth in NAV per share, reaching 110p (GBP 1.10), driven by significant value crystallization from a Pfizer obesity drug royalty interest and robust cash exits totaling GBP 68 million.

• Generated GBP 68 million in cash exits, enabling reinvestment in high-conviction opportunities and a GBP 45 million share buyback, retiring nearly 9% of shares at a 50% discount to NAV.

• Portfolio companies raised over GBP 900 million in third-party capital, with strong syndicates and notable funding rounds (e.g., Artios, Oxa, Microbiotica).

• Achieved successful exits, including Hinge Health's NYSE IPO at a ~$3bn valuation (53x return) and Monolith's acquisition by CoreWeave (70% IRR).

• Maintained a strong balance sheet with gross cash of GBP 211 million at year-end.

Financial highlights

• NAV per share increased 13% year-over-year to 110p (GBP 1.10), with overall profit of GBP 67 million and total NAV reaching GBP 975.1 million.

• Overheads reduced to 15.9% of income (1.6% of NAV), down from 22.1% two years prior.

• Portfolio value rose from GBP 850 million to over GBP 900 million, with GBP 71 million invested and GBP 68 million realized in exits.

• Fair value gain of GBP 64 million, mainly from the Pfizer obesity royalty interest, now valued at GBP 128 million.

• Cash balance at GBP 211 million, with net cash at GBP 88.2 million after debt.

Outlook and guidance

• Priorities for FY25–FY27 include continued NAV per share growth, disciplined capital deployment, and maintaining balance sheet flexibility.

• Plans to launch further share buybacks if discount to NAV persists and to make first investments from the Aberdeen partnership.

• Targeting GBP 250 million in realizations over the next phase, with a focus on maturing portfolio companies and liquidity events.

• Targeting EBITDA break-even by FY27.